MRSN Stock Overview
A clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Mersana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.98 |
| 52 Week High | US$6.28 |
| 52 Week Low | US$1.22 |
| Beta | 1.47 |
| 11 Month Change | -3.41% |
| 3 Month Change | 26.92% |
| 1 Year Change | 32.44% |
| 33 Year Change | -74.52% |
| 5 Year Change | -42.11% |
| Change since IPO | -85.86% |
Recent News & Updates
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?
Nov 08
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03Recent updates
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?
Nov 08Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade
Aug 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%
Aug 13Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues
Jun 19Mersana Therapeutics: On Hold While Waiting For Any Positive News
May 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Shareholder Returns
| MRSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.4% | -6.5% | -1.0% |
| 1Y | 32.4% | 14.6% | 30.3% |
Return vs Industry: MRSN exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: MRSN exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| MRSN volatility | |
|---|---|
| MRSN Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRSN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MRSN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 123 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Mersana Therapeutics, Inc. Fundamentals Summary
| MRSN fundamental statistics | |
|---|---|
| Market cap | US$274.24m |
| Earnings (TTM) | -US$74.62m |
| Revenue (TTM) | US$34.84m |
7.0x
P/S Ratio-3.3x
P/E RatioIs MRSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRSN income statement (TTM) | |
|---|---|
| Revenue | US$34.84m |
| Cost of Revenue | US$72.23m |
| Gross Profit | -US$37.39m |
| Other Expenses | US$37.23m |
| Earnings | -US$74.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | -107.33% |
| Net Profit Margin | -214.19% |
| Debt/Equity Ratio | 2,426.8% |
How did MRSN perform over the long term?
See historical performance and comparison